IRVINE, Calif., Aug. 24 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals,
Inc. (Nasdaq: ISTA), today announced it will present at the following
upcoming investor conferences:
Roth 2007 New York Conference
ISTA's Chief Financial Officer and Vice President of Corporate
Development, Lauren Silvernail, will provide an update on the Company's
commercial and clinical progress at 2:00 p.m. Eastern Time on Wednesday,
September 5, 2007 at The Westin New York at Times Square.
Thomas Weisel Partners Healthcare Conference
ISTA's President and Chief Executive Officer, Vicente Anido, Jr., Ph.D.
will provide an update on the Company's commercial and clinical progress at
9:45 a.m. Eastern Time on Thursday, September 6, 2007 at the Four Seasons
Boston.
To access the live audio broadcasts or the subsequent archived
recordings, log onto http://www.istavision.com. Please connect to the
website several minutes prior to the start of the conference call to ensure
adequate time for any software download that may be necessary.
About ISTA
ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's
products and product candidates addressing the $3.2 billion U.S.
prescription ophthalmic industry include therapies for inflammation, ocular
pain, glaucoma, allergy, and dry eye. The Company currently markets three
products and is developing a strong product pipeline to fuel future growth
and market share. The Company's product development and commercialization
strategy is to launch a new product every 12 to 18 months, thereby
continuing its growth to become the leading niche ophthalmic pharmaceutical
company in the U.S. For additional information regarding ISTA, please visit
ISTA Pharmaceuticals' website at http://www.istavision.com.
SOURCE ISTA Pharmaceuticals
 back to top
Related links:
http://www.istavision.com
CONTACT:
Vince Anido, +1-949-788-5311,
vanido@istavision.com; Lauren Silvernail, +1-949-788-5302,
lsilvernail@istavision.com, both of ISTA Pharmaceuticals; or
Justin Jackson (Media), Burns McClellan, jjackson@burnsmc.com;
Juliane Snowden (Investors), Burns McClellan, +1-212-213-0006,
jsnowden@burnsmc.com, both for ISTA Pharmaceuticals
|
